Lymphotoxin beta receptor (LTβR)
Assets acting on this target.
- Class
- Lymphotoxin beta receptor fusion protein (LTβR-Ig)
- Notes
- mechanism wave 2026-08-24 (PubMed co-occurrence, 108 article(s)); source: https://pubmed.ncbi.nlm.nih.gov/42012978/
Assets acting on this target.
3 of 3 assets (3 discontinued)
| Drug | Owner | Mechanism | Indication | Reached | Why it stopped | Source |
|---|---|---|---|---|---|---|
| Baminercept alfa 1 | Biogen | Lymphotoxin beta receptor (LTβR) | Rheumatoid Arthritis | Ph 2 | SafetyThis is one of five dose-arm entries for baminercept alfa (BG9924), whose RA trial was terminated by Biogen in 2008 with no subsequent RA development. | source ↗ |
| Baminercept alfa 2 | Biogen | Lymphotoxin beta receptor (LTβR) | Rheumatoid Arthritis | Ph 2 | This is one of five dose-arm entries for baminercept alfa (BG9924), whose RA trial was terminated by Biogen in 2008 with no subsequent RA development. | source ↗ |
| BG9924 | Biogen | Lymphotoxin beta receptor (LTβR) | Rheumatoid Arthritis | Ph 2 | Biogen's BG9924 was tested in several rheumatoid arthritis trials from 2005-2008, most of which were terminated; no BG9924 trial has been registered since 2008, consistent with the program being discontinued. | source ↗ |